Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04628338 · ClinicalTrials.gov registry record · Early Phase 1
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
A Early Phase 1 study, sponsored by Sawa Ito, MD.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT04628338 is a Early Phase 1 study that has completed, run by Sawa Ito, MD. The registered enrollment target is 8 participants.
The verdict
NCT04628338, a Early Phase 1 study, has completed, sponsored by Sawa Ito, MD.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study proposes a safe dosing regimen IFN-γ that is sufficient to stimulate IFN-γ receptors on malignant blasts in patients who developed relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after alloSCT with no active or history of III-IV acute graft-versus-host disease (GVHD). It is hypothesized that IFN-γ will promote graft-vs-leukemia (GVL) in patients with AML/MDS that has relapsed after alloSCT.
Interventions
- DRUG IFN-γ (interferon gamma-1b) injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-03-08 |
| Est. Completion | 2023-10-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04628338
The ClinicalTrials.gov registry entry for NCT04628338 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sawa Ito, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IFN-γ (interferon gamma-1b) injection is the first listed.
NCT04628338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04628338 about?
NCT04628338 is a clinical study titled "IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation". This study proposes a safe dosing regimen IFN-γ that is sufficient to stimulate IFN-γ receptors on malignant blasts in patients who developed relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after alloSCT with no active or history of III-IV acute graft-versus-host disease (GVH...
What is the current status of trial NCT04628338?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2021-03-08. Estimated completion is 2023-10-30.
What interventions are being tested in trial NCT04628338?
The interventions under investigation include: IFN-γ (interferon gamma-1b) injection (DRUG).
Who is sponsoring clinical trial NCT04628338?
This trial is sponsored by Sawa Ito, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.